Compare AVNT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNT | BEAM |
|---|---|---|
| Founded | 1927 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2000 | 2019 |
| Metric | AVNT | BEAM |
|---|---|---|
| Price | $37.52 | $25.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $41.50 | ★ $50.75 |
| AVG Volume (30 Days) | 934.8K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $3,835,500,000.00 | $24,000.00 |
| Revenue This Year | $4.90 | N/A |
| Revenue Next Year | $3.48 | $33.77 |
| P/E Ratio | $60.07 | ★ N/A |
| Revenue Growth | 1.71 | ★ 33.33 |
| 52 Week Low | $27.48 | $15.60 |
| 52 Week High | $44.85 | $38.26 |
| Indicator | AVNT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 30.23 |
| Support Level | $35.25 | $24.80 |
| Resistance Level | $37.88 | $33.32 |
| Average True Range (ATR) | 1.18 | 1.99 |
| MACD | 0.03 | -0.94 |
| Stochastic Oscillator | 56.84 | 1.83 |
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two reportable segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The Color, Additives, and Inks segment and the distribution segment generate maximum revenue. Geographically, the company generates maximum revenue from the United States and Canada, followed by EMEA, Asia, and Latin America.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.